Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMA1-C1 + ISA 720
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AMA1-C1 + ISA 720 is a blood-stage malaria vaccine candidate that combines the recombinant protein vaccine apical membrane antigen 1-Combination 1 (AMA1-C1) formulated with Montanide ISA 720, a water-in-oil adjuvant. AMA1-C1 contains an equal mixture of recombinant proteins based on sequences from the FVO and 3D7 clones of Plasmodium falciparum. The vaccine aims to induce antibodies against the blood stage of malaria parasites. In clinical trials, it demonstrated immunogenicity in malaria-naïve adults, though some transient, severe, and late local reactions were observed. The vaccine showed dose-dependent antibody responses with in vitro growth-inhibitory activity against malaria parasites.
- Other names
- AMA1-C1 formulated in Montanide ISA 720AMA-1-C1 formulated in Montanide ISA 720AMA 1-C1 formulated in Montanide ISA 720AMA1-C1/Montanide ISA 720
02
Targets
AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on AMA1-C1 + ISA 720.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMA1-C1 + ISA 720.